Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dSgcCduTtWCepFuXCidmzaCicNutBN
- Onconova licenses cancer drug rigosertib to Baxter
Baxter secured the European rights to Onconova's targeted cancer drug rigosertib. The drug is under clinical development against myelodysplastic syndromes and pancreatic cancer. The deal entitles Oncova to $50 million upfront and as much as $515 million for development and regulatory milestones. Onconova also could receive sales milestones and royalties. Genetic Engineering & Biotechnology News (9/19)       | Potential Sickle Cell Disease Treatments on the Horizon | | Brian Culley, CEO of Adventrx Pharmaceuticals Inc., is a busy man these days. Not only is his company readying itself for an important Phase III trial, but he is also organizing the first Sickle Cell Disease Therapeutics Conference that will be held this week in NYC. Find out the details. |  |
| Health Care & Policy |  |  | | - Forest-Ironwood IBS drug Linzess beats placebo in Phase III trials
Two late-stage trials found that more patients with irritable bowel syndrome who took Forest Laboratories and Ironwood Pharmaceuticals' Linzess, or linaclotide, experienced significant reduction in abdominal pain and constipation than those who received placebo. The studies helped pave the way for the drug's FDA approval, said Dr. William Chey, lead researcher of one of the studies. HealthDay News (9/18) - Navidea kicks off trial of Alzheimer's imaging agent
Navidea Biopharmaceuticals said it has started enrollment for a midstage trial to test the safety and efficacy of its fluorine-18 NAV4694 imaging agent in identifying cerebral beta amyloid plaque in patients who may have Alzheimer's disease. The study will also determine whether neuropsychiatric test findings correspond with measured amounts of beta amyloid. AuntMinnie.com (free registration) (9/18) - 3 drugmakers test novel vaccines to fight MRSA
NovaDigm Therapeutics, GlaxoSmithKline and Pfizer are testing vaccines against methicillin-resistant Staphylococcus aureus, which is finding its way into prisons, schools and day care centers. The vaccines are years away from potential approval because they are still in early trials. NovaDigm's vaccine triggers an immune system response to destroy the bug before it affects the body, while GSK's and Pfizer's vaccines directly attack various biological fronts. Bloomberg Businessweek (9/17)  | Earn 2X rewards points on shipping costs with The Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, and shipping
• 1X points on everything else
• Limited Time Offer: 50K bonus points when you spend $5K in your first 3 months of Card membership†
LEARN MORE AND APPLY †Terms & Restrictions Apply. |
  | Company & Financial News | | | | | Industry Deals | | | |
| Food & Agriculture | | | | | Industrial & Environmental | | | | - Algae.Tec partners with Lufthansa to produce aviation biofuels
German airline Lufthansa and Australian biofuels maker Algae.Tec entered into an agreement to build a large-scale manufacturing plant for algae-based aviation biofuels at a site in Europe. "Lufthansa will arrange 100% funding for the project," according to a statement from Algae.Tec. Lufthansa will buy at least half of the facility's biofuel. Reuters (9/19) | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | Cooperation is the thorough conviction that nobody can get there unless everybody gets there."
--Virginia Burden Tower,
American writer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, September 19, 2012
- Tuesday, September 18, 2012
- Monday, September 17, 2012
- Friday, September 14, 2012
- Thursday, September 13, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment